Multiple endocrine neoplasia type 1 other diagnostic studies

Multiple endocrine neoplasia type 1 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multiple endocrine neoplasia type 1 other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 1 other diagnostic studies
CDC on Multiple endocrine neoplasia type 1 other diagnostic studies
Multiple endocrine neoplasia type 1 other diagnostic studies in the news
Blogs on Multiple endocrine neoplasia type 1 other diagnostic studies
Directions to Hospitals Treating Multiple endocrine neoplasia type 1
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Genetic Testing

• Identifying an MEN1 gene mutation in the proband early in the disease process can allow for early detection and treatment of tumors and earlier identification of at-risk family members.
• Many studies have been performed to determine the prevalence of MEN1 gene mutations among patients with apparently sporadic MEN1-related tumors.
• Genetic testing for mutations in MEN1 is recommended if one of the following conditions is present

• Gastrinoma at any age.
• Multifocal duodenopancreatic NETs at any age
• Parathyroid hyperplasia/adenomas before age 30 or 40 years
• Multiglandular parathyroid adenomas/hyperplasia or recurrent PHPT
• Presence of one of the three main MEN1 tumors plus one of the less common tumors/findings
• Presence of two or more features (e.g., adrenal adenomas and carcinoid tumor)